NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. A closeup of a vial of the ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

The FDA recently approved new COVID-19 vaccines for Americans, but due to certain restrictions, there has been mounting confusion on what they are, how much protection they’ll offer and whether ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

DURHAM, N.C. -- Two of the COVID-19 vaccines currently in use in the United States will be effective against a variant of the virus that was first identified in California, according to researchers at ...

That might sound crazy. After all, Novavax is tiny and unproven. It's losing millions of dollars every quarter. Meanwhile, Merck is an established big pharma company that makes more money from just ...

CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...